Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$10.1B
99M shares
52-week range
$92.77 – $127.99
22% from low
Sector
SERVICES-HOSPITALS
Exchange
NYSE
CS
Borrow rate
0.27%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.28B | $4.61B | $3.57B | $4.01B | $4.35B | $4.80B | $5.37B | $5.94B |
| Cost of revenue | $158.7M | $167.9M | $171.0M | $2.31B | $2.60B | $2.82B | $3.14B | $254.4M |
| Gross profit | $4.12B | $4.44B | $3.40B | $1.70B | $1.75B | $1.98B | $2.23B | $5.68B |
| Gross margin | 96.3% | 96.4% | 95.2% | 42.4% | 40.3% | 41.3% | 41.6% | 95.7% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $681.6M | $692.5M | $0 | $659.4M | $630.2M | $1.72B | $864.5M | $1.05B |
| EBITDA | $840.2M | $940.7M | $739.6M | $888.9M | $870.1M | $1.01B | $1.19B | $1.40B |
| Net income | $292.3M | $358.7M | $284.2M | $412.2M | $271.0M | $352.0M | $455.7M | $566.2M |
| Net margin | 6.8% | 7.8% | 8.0% | 10.3% | 6.2% | 7.3% | 8.5% | 9.5% |
| EPS (diluted) | 2.93 | 3.61 | 2.85 | 4.11 | 2.70 | 3.47 | 4.46 | 5.54 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.4B | $6.01 | $5.78–$6.10 | 9 |
| 2027 | $6.9B | $6.54 | $6.23–$6.69 | 9 |
| 2028 | $7.5B | $7.28 | $6.78–$7.59 | 3 |
| 2029 | $8.2B | $8.37 | $8.33–$8.41 | 1 |
Forward consensus · source: Financial Modeling Prep
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
www.encompasshealth.comNo one on the platform currently holds EHC.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 265,000 | $25.6M |
| Bridgewater Associatesas of 2026-03-31 | 46,415 | $4.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-01 | $0.1900 | 2026-07-15 |
| 2026-04-01 | $0.1900 | 2026-04-15 |
| 2026-01-02 | $0.1900 | 2026-01-15 |
| 2025-10-01 | $0.1900 | 2025-10-15 |
| 2025-07-01 | $0.1700 | 2025-07-15 |
| 2025-04-01 | $0.1700 | 2025-04-15 |
| 2025-01-02 | $0.1700 | 2025-01-15 |
| 2024-10-01 | $0.1700 | 2024-10-15 |
| 2024-07-01 | $0.1500 | 2024-07-15 |
| 2024-03-28 | $0.1500 | 2024-04-15 |
No one on the platform has traded EHC yet.
| $12.4B |
| — |
| ENSGThe Ensign Group, Inc. | $158.19 | -2.98% | $9.2B | — |
| FMSFresenius Medical Care AG & Co. KGaA | $22.70 | -2.32% | $12.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-12-29 |
| $0.1500 |
| 2024-01-16 |
| 2023-09-29 | $0.1500 | 2023-10-16 |
Trading at 20.8× earnings vs its 19.4× historical median P/E.
Fair value ≈ $93.83 · price $100.48 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$EHC Current Stock Price: $99.93 Contracts to trade: $100.0 EHC Jul 17 2026 Call Entry: $2.90 Exit: $5.11 ROI: 76% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗Wall St is expecting 1.48 EPS for $EHC Q2 [Reporting 08/04 AMC] http://www.estimize.com/intro/ehc?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗https://marketbeat.com/a/8708040/ $UNH $HCA $EHC Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit
View on StockTwits ↗$EHC Share Price: $105.92 Contract Selected: Dec 18, 2026 $105 Calls Buy Zone: $9.09 – $11.23 Target Zone: $14.85 – $18.15 Potential Upside: 54% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$EHC Price: $104.45 (-0.35%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±0.79% RSI: 55.5 | Momentum: Moderate Volume: -99.0% vs avg Volatility: 2.15% Support: $98.28 | Resistance: $109.32 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
View on StockTwits ↗$EHC Healthcare providers and medical device manufacturers report strong Q1 2026 earnings driven by product approvals, expanded commercial investments, and accelerating procedure volumes with margin expansion from operational efficiency. Learn more: https://axlfi.com/themes/220
View on StockTwits ↗$EHC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.96 up 30.67% YoY • Reported revenue of $1.59B up 9.01% YoY • Encompass Health increased its full-year 2026 guidance, expecting net operating revenue of $6,375 million to $6,470 million, Adjusted EBITDA of $1,350 million to $1,380 million, and adjusted earnings per share of $5.89 to $6.11.
View on StockTwits ↗$EHC Pre-catalyst positioning shows foresight. Post-catalyst stacking shows confirmation. When both happen within 30–60 days, conviction layer doubles. That’s how breakouts get engineered 🚀🔥
View on StockTwits ↗$EHC beats Q4 adjusted EPS estimates — but why the Zacks Rank #4 (Sell)? 🤔 Encompass Health posted a 13.2% adjusted EPS beat and a 24.8% YoY increase in adjusted EPS, driven by higher revenues per discharge and increased discharges. Yet, rising operating expenses, particularly salaries and benefits, which escalated 7.5% YoY, remain a concern. Full analysis here 👉 https://www.zacks.com/stock/news/2842430/encompass-health-q4-earnings-beat-but-discharges-lag?cid=sm-stocktwits-2-2842430-body-32711&ADID=SYND_STOCKTWITS_TWEET_2_2842430_BODY_32711
View on StockTwits ↗$EHC Q4 earnings beat — but operational headwinds linger ⚠️ EPS and revenue topped estimates, boosted by higher revenue per discharge, yet rising salaries and benefits weighed on results. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2842430/encompass-health-q4-earnings-beat-but-discharges-lag?cid=sm-stocktwits-2-2842430-teaser-32709&ADID=SYND_STOCKTWITS_TWEET_2_2842430_TEASER_32709
View on StockTwits ↗$EHC Share Price: $105.90 Contract Selected: Jul 17, 2026 $115 Calls Buy Zone: $4.33 – $5.35 Target Zone: $7.78 – $9.50 Potential Upside: 69% ROI Time to Expiration: 160 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$EHC Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $1.45 up 20.83% YoY • Reported revenue of $1.54B up 9.94% YoY • Encompass Health projects 2026 net operating revenue between $6.37B and $6.47B, Adjusted EBITDA from $1.34B to $1.38B, and Adjusted earnings per share from $5.81 to $6.10.
View on StockTwits ↗$EHC reports after the close, Estimize Consensus +0.06 EPS and +7.37M Revs compared to WS http://www.estimize.com/ehc/fq4-2025?utm_content=
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.